

Altus Pharmaceuticals Inc.
Form 8-K
June 02, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

May 30, 2008

Altus Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction
of incorporation)

0-51711

(Commission
File Number)

04-3573277

(I.R.S. Employer
Identification No.)

640 Memorial Drive, Cambridge,
Massachusetts

(Address of principal executive offices)

02139

(Zip Code)

Registrant's telephone number, including area code:

617-299-2900

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(a), (c), (d), (e) and (f): Not Applicable.

(b) Effective May 30, 2008, David D. Pendergast, Ph.D. resigned as the interim Executive Chairman of Altus Pharmaceuticals Inc. (the "Company") in connection with the appointment of Georges Gemayel, Ph.D. as the Company's new President and Chief Executive Officer. Dr. Pendergast will continue to serve as the Company's Chairman of the Board of Directors.

Edgar Filing: Altus Pharmaceuticals Inc. - Form 8-K

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Altus Pharmaceuticals Inc.

May 30, 2008

By: *Jonathan I. Lieber*

Name: Jonathan I. Lieber

*Title: Senior Vice President, Chief Financial Officer and
Treasurer*